JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

Search

Bio-Techne Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

55.44 8.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

51.27

Max

55.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-176K

38M

Pardavimai

9.3M

296M

P/E

Sektoriaus vid.

103.981

67.147

Dividendų pajamingumas

0.59

Pelno marža

12.846

Darbuotojai

3,100

EBITDA

-135K

78M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+38.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.59%

2.36%

Kitas uždarbis

2026-05-06

Kitas dividendų mokėjimo data

2026-05-29

Kita Ex Dividend data

2026-05-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.5B

8.6B

Ankstesnė atidarymo kaina

46.93

Ankstesnė uždarymo kaina

55.44

Naujienos nuotaikos

By Acuity

41%

59%

173 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Bio-Techne Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-07 22:36; UTC

Uždarbis

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Bio-Techne Corp Prognozė

Kainos tikslas

By TipRanks

38.59% į viršų

12 mėnesių prognozė

Vidutinis 72 USD  38.59%

Aukščiausias 80 USD

Žemiausias 54 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bio-Techne Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

5

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

49.67 / 50.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

173 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat